Research programme: RNAi therapeutics- Mallinckrodt/Silence Therapeutics
Alternative Names: SLN-500; SLN-MNK-3; SNL MNK 3; SNL-MNK-2Latest Information Update: 28 Oct 2023
At a glance
- Originator Silence Therapeutics
- Class RNA
- Mechanism of Action Complement C3 inhibitors; Complement system protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders; Metabolic disorders; Unspecified
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
- 28 Aug 2023 No recent reports of development identified for research development in Metabolic-disorders in USA (Parenteral)
- 28 Aug 2023 No recent reports of development identified for research development in Unspecified in USA (Parenteral)